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Norgestrel and gestodene stimulate breast cancer cell growth through an
oestrogen receptor mediated mechanism
W.H. Catherino, M.H. Jeng & V.C. Jordan
Department ofHuman Oncology, University of Wisconsin Comprehensive Cancer Center, 600 Highland Avenue, Madison,
Wisconsin 53792, USA.
Summary There is great concern over the long-term influence of oral contraceptives on the development of
breast cancer in women. Oestrogens are known to stimulate the growth of human breast cancer cells, and this
laboratory has previously reported (Jeng & Jordan, 1991) that the 19-norprogestin norethindrone could
stimulate the proliferation of MCF-7 human breast cancer cells.
We studied the influence of the 19-norprogestins norgestrel and gestodene compared to a 'non' 19-
norprogestin medroxyprogesterone acetate (MPA) on MCF-7 cell proliferation. The 19-norprogestins
stimulated proliferation at a concentration of 10-8 M, while MPA could not stimulate proliferation at
concentrations as great as 3 x 10-6 M. The stimulatory activity of the 19-norprogestins could be blocked by the antioestrogen ICI 164,384, but not by the antiprogestin RU486.
Transfection studies with the reporter plasmids containing an oestrogen response element or progesterone
response element (vitERE-CAT, pS2ERE-CAT, and PRE15-CAT) were performed to determine the intracel-
lular action of norgestrel and gestodene. The 19-norprogestins stimulated the vitERE-CAT activity maximally
at 10-6 M, and this stimulation was inhibited by the addition of ICI 164,384. MPA did not stimulate
vitERE-CAT activity. A single base pair alteration in the palindromic sequence of vitERE (resulting in the
pS2ERE) led to a dramatic decrease in CAT expression by the 19-norprogestins, suggesting that the progestin
activity required specific response element base sequencing. PRE15-CAT activity was stimulated by norgestrel,
gestodene and MPA at concentrations well below growth stimulatory activity. This stimulation could be
blocked by RU486. These studies suggest that the 19-norprogestins norgestrel and gestodene stimulate MCF-7
breast cancer cell growth by activating the oestrogen receptor.
Millions of women benefit from oral contraceptives, a low-
cost, low-toxicity, highly effective form of birth control.
Studies assessing long-term risks associated with oral contra-
ceptive use suggest that cancer risk of the endometrium
(Salmi, 1979; Weiss & Sayvets 1980; Kaufman et al., 1980;
Layde, 1982; Hulka et al., 1982) and the ovary (Layde, 1982;
Newhouse it al., 1977; McGowan et al., 1979; Casagrande et
al., 1979; Rosenberg et al., 1982) are decreased. The influence
of oral contraceptives on the development of breast cancer
remains controversial, with studies suggesting no effect
(McPherson et al., 1983; Wiseman, 1983; Sattin et al., 1986;
Buehring, 1988; Stadel, 1988; Schlesselman, 1989) or a slight
increased effect on incidence (Pike et al., 1983; Olsson et al.,
1985; Meirik et al., 1986; Longman & Buehring, 1987;
McPherson et al., 1987, Kay & Hannaford, 1988; Peto, 1989;
Olsson et al., 1989). In the United States, oral contraceptives
have been used for 30 years, and therefore the influence of
oral contraceptives on breast cancer may become apparent in
the coming years as the first cohort of women to use oral
contraceptives begin to enter menopause in large numbers.
Oestrogen is well known as an effective mitogen in the
breast, but only recently has attention focused on the possi-
ble effects of the progestin as a potential stimulatory factor.
Laboratory (Drill, 1977; Braunsberg et al., 1986; Haslam,
1988) and clinical (Pike et al., 1983; Henderson et al., 1988;
Paul et al., 1989; Bergkvist et al., 1989; Anderson et al.,
1989) data suggested a possible stimulatory role for proges-
tins in breast cancer incidence. Other studies (Stoll, 1967;
L0ber et al., 1981; Liang et al., 1983; Sutherland et at., 1988;
Alexander et al., 1990; Abrams et al., 1990; Dauvois et al.,
1990; Pap et al., 1991) appeared to refute progestin-mediated
breast mitogenesis.
Our laboratory has approached this problem by develop-
ing a working hypothesis on progestin-mediated breast
cancer cell proliferation. We suggest that the orally active
progestational 19-nortestosterone derivatives are growth
stimulatory in the breast. Our previous work (Jeng & Jordan,
1991) has shown that the 19-norprogestin norethindrone is
effective in stimulating MCF-7 cell growth, and that this
stimulation can be inhibited by the antioestrogen 4-
hydroxytamoxifen.
In this study, we examined the 19-norprogestins norgestrel
and gestodene to determine if these compounds also pos-
sessed oestrogen-like activity. All structures are shown in
Figure 1. Norgestrel is the sole hormonal agent in the sub-
cutaneous contraceptive device NORPLANT* which is cur-
rently used by hundreds of thousands of women worldwide.
Because of its convenience and effectiveness, NORPLANTJD
may replace oral contraceptives as the most accepted means
of contraception. Gestodene has proven to be a potent 19-
norprogestin (Pollow et al., 1989) with a low incidence of
side effects (Phillips, 1990). As a result, gestodene may
become a popular alternative to other 19-norprogestins.
Iqbal et al. (1986) have found that gestodene is growth
inhibitory in human breast cancer cell lines. They demon-
strate a novel gestodene receptor that can interact with ges-
todene but not its similar structural homologue, norgestrel.
Further work by Colletta et al. (1991) suggests that the
gestodene-induced growth inhibitory activity is mediated via
TGF-P production. By contrast, our previous results (Jeng &
Jordan, 1991), using a structurally similar progestin, showed
a growth stimulatory influence. This contradiction has led us
to investigate norgestrel and gestodene in our model system.
We examined the proliferation of MCF-7 cells in culture in
the presence of the 19-norprogestins norgestrel and ges-
todene, as well as MPA, a commonly used progestin that is
not a 19-nor steroid. We also examined the influence ofeither
the pure antioestrogen ICI 164, 384 or the antiprogestin
RU486 on progestin-stimulated growth. CAT assays were
performed using the vitERE, pS2ERE or PRE15 DNA bin-
ding sites in conjunction with the CAT gene to determine the
intracellular interaction of the progestin with steroid recep-
tors. The plasmids transfected are constructed with either the
oestrogen response element (ERE) or the progesterone re-
sponse element (PRE) attached to a promotor and then to
the chloramphenicol acetyltransferase gene (CAT). Specific
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Figure 1 The chemical structures of the compounds used in this study. The 19-norprogestins can be distinguished by the lack of a
methyl group in the position between the A and B rings.
binding of the activated oestrogen or progesterone receptor
to its respective response element results in CAT expression.
Therefore, the CAT protein serves as a 'reporter' of activated
receptor. Our results suggest that there is a growth pro-
liferative effect of the 19-norprogestins on the MCF-7 cell
line at concentrations that are likely to be achieved during
oral contraceptive administration. A strategy of defining the
health risk/benefits ofcontraceptives based upon total oestro-
genicity is discussed.
Materials and methods
Cell Culture
MCF-7 cells (Soule et al., 1973) were originally obtained
from the Michigan Cancer Foundation. Cells were grown in
minimal essential medium containing 5% (vol/vol) calf serum
supplemented with 0.29 mg ml-' L-glutamine, 100 U ml-'
penicillin plus 1I00 g ml-' streptomycin, 6 ng ml-' bovine
insulin (Sigma Chemical Co., St. Louis, MO), 0.35 g
NaHCO3 liter, and 25 mM HEPES. Cells were harvested by
an initial wash with calcium- and magnesium-free Hanks'
Balanced Salt Solution, followed by trypsinisation. Cells were
tested for mycoplasma using GEN-PROBE@ rapid detection
system (GEN-PROBE Inc, San Diego, CA) every 2 months
and all cells were free of mycoplasma.
Hormone treatment
Twenty four well plates were seeded with 15,000 MCF-7 cells
in 1 ml ofphenol red containing minimal essential medium per
well. The next day, the media was changed to medium without
phenol red. The cells were deprived of steroid for 5 days.
Medium was changed every other day. Compounds were then
added at the indicated concentrations, and media with com-
pound were changed every other day for a total of 6 days. All
compounds were dissolved in 100% ethanol, and added to the
media in 1:1000 dilution for a final ethanol concentration no
greater than 0.2%. Oestradiol, norgestrel and MPA were pur-
chased from Sigma Chemical Co. (St Louis, MO); ICI 164,
384 was obtained from ICI pharmaceuticals (Macclesfield,
England); RU486 was obtained from Roussel; gestodene was a
gift from Berlex Laboratories, Inc. (Cedar Knolls, NJ). After
the sixth day in the presence of compound, the media was
removed and the cells were lysed by sonication for 20 s using a
Kontes ultrasonic cell disruptor in 1 ml of calcium- and
magnesium-free Hanks' Balanced Salt Solution. Total DNA
per well was measured fluorometrically by incubating samples
with Hoechst dye 33258 (Calbiochem-Behring Corp, La Jolla,
CA) according to a method by LaBarca and Paigen (LaBarca
& Paigen, 1980) and analysed on an SLM-Aminco Fluoro-
colorimeter III (SLM Instruments, Urbana, IL). Each data
point represents a mean of triplicate wells.
Transfection and CAT assay
(a) ERE-CAT assays Two million MCF-7 cells were plated
in 10 cm dish in oestrogen free medium for 3 days and then
transfected with plasmid DNA using the calcium phosphate
coprecipitation method. Plasmid vitERE contains the ERE
derived from the vitellogenin gene and thymidine kinase
promoter derived from herpes simplex virus (vitERE-TK-
CAT) (Klock et al., 1987). The reference plasmid pCMVP,
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which constitutively produces P-galactosidase, (MacGregor &
Caskey, 1989) was used as a measure of transfection
efficiency for all transfection studies. The imperfect palin-
drome (pS2ERE) was used in place of the vitERE in similar
experiments. Cells were transfected with 10ytg of reporter
plasmid together with 5fg of pCMV0 for 6 h and then
treated with 10% glycerol in oestrogen free media for 3 min.
Media containing various compounds were then added for
48 h. Cells were harvested and cytosol extracts were prepared
by 3 cycles of freezing/thawing (liquid nitrogen/37°C). The
activity of P-galactosidase in cytosol extracts was measured
using 0-nitrophenyl P-D-galactopyranoside as the substrate.
Aliquots of cytosol extracts containing equal amounts of
P-galactosidase activity were used for the CAT assay in
150,lI reaction volumes containing 0.25M Tris-HCI pH 7.5,
0.6 mM acetyl CoA (Sigma Chemical Co., St. Louis, MO),
0.05fsCi [14C] chloramphenicol (55 gLCi mmole 1, Amersham,
Arlington Heights, II). The acetylated and nonacetylated
forms of ['4C] chloramphenicol were separated by TLC
(chloroform :methanol 19:1). The radioactive spots were
scraped from the plates into scintillation vials containing 5 ml
of Poly-Flourm scintillation fluid, and counts per minute per
spot was measured by a Tracor Analytic Mark III scintilla-
tion counter.
(b) PRE15-CAT assays MCF-7 cells that are oestrogen de-
prived possess a low progesterone receptor content. A low
receptor content results in a very weak signal when using the
transient transfection assay as described above. Therefore, an
approach was necessary to boost progesterone receptor con-
tent. This problem was solved by supplementing the steroid-
free media with 10-10M oestradiol. All other steps for tran-
sient were as described above, except that the PRE15-CAT
plasmid construct was used.
Results
Norgestrel andgestodene influence on MCF-7 cellgrowth in
vitro
The ability of oestradiol to stimulate proliferation of MCF-7
cells in vitro is well documented. We studied the influence of
the compounds norgestrel, gestodene and MPA on the pro-
liferation of MCF-7 cells relative to oestradiol stimulation.
The results are depicted in Figure 2. The control level
represents the DNA content observed when no steroid was
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added. Oestradiol at 10-'3 M (0.27 pg ml-') is unable to
stimulate cell proliferation beyond the control level, whereas
an increase in concentration of 2 logs could stimulate max-
imal proliferation. Maximal proliferation was approximately
6-fold over control. Norgestrel and gestodene were similar in
their ability to stimulate cell proliferation. Both compounds
were unable to stimulate proliferation above control levels at
10-9 M (3.125 ngml-' and 3.105 ngml-', respectively).
Maximal stimulation occurred after a 3 log increase in con-
centration. This level of stimulation provided a 5-fold in-
crease in DNA content. MPA was unable to stimulate cell
proliferation above control levels at all concentrations tested.
Concentrations of 10-5 M or higher were not tested because
these concentrations are known to be toxic to MCF-7 cells in
vitro (unpublished results). Neither oestradiol, gestodene, nor
norgestrel were able to stimulate the oestrogen receptor
negative cell (MDA-MB-231) proliferation at the concentra-
tions tested above (data not shown).
The influence ofoestrogen, norgestrel andgestodene on MCF-7
cellproliferation in the presence ofthe antioestrogen ICI
164,384
Because norgestrel and gestodene were capable ofstimulating proliferation, the mechanism of such stimulation became the
focus of our work. Since proliferation is also seen with
oestrogen, we studied the influence that an antioestrogen has
on progestin-mediated proliferation. The antioestrogen ICI
164, 384 is a pure antioestrogen (Wakeling & Bowler, 1988), and was used instead of tamoxifen because of the known
stimulatory capability of tamoxifen itself on MCF-7 cell
proliferation (Cormier & Jordan, 1989). The effect of oest-
radiol and gestodene with and without ICI 164, 384 are
shown in Figure 3. In the presence of a constant concentra-
tion of ICI 164, 384 of 10-6 M, oestradiol is not capable of
stimulating cell proliferation except at the highest concentra-
tion tested (Figure 3). Even at this concentration, oestradiol
was not capable of stimulating cell proliferation maximally. Gestodene was unable to reverse the inhibitory action of ICI
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Figure 2 The influence of oestradiol (0), norgestrel (@), ges-
todene (0), and MPA (O) in MCF-7 cell growth. The control
level indicates the DNA level measured when cells were grown in
the absence of steroid. Cells were seeded in 24 well plates at a
density of 15,000 cells/well (in phenol minus minimal essential
media with 5% stripped calf serum) and were deprived of oest-
rogen for 5 days. Compounds were then added at the concentra-
tions indicated and media was changed every other day. After 6
days, the cells were disrupted and a 50 il cellular extract from
each well was assayed for DNA content. Each concentration was
done in triplicate.
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Figure 3 The influence of oestradiol (0) and gestodene on MCF-7 cells with and without the presence of ICI 164, 384. The protocol used is the same as that described in the legend under Figure 2. The ICI 164, 384 concentration used was 10-6M (0), and varying concentrations of oestradiol plus 10-6M ICI 164, 384
are represented by (0). Varying concentrations of gestodene plus 10-6 M ICI 164, 384 are represented by (0). Norgestrel results in this assay were similar to gestodene and were thus not included to improve the clarity of the figure.948 W.H. CATHERINO et al.
164, 384 at all concentrations tested. Norgestrel was also not
capable of stimulating cell proliferation above control levels
in the presence of 10-6 M ICI 164, 384 (data not shown).
The influence ofoestradiol, norgestrel andgestodene on
MCF-7 cellgrowth in thepresence ofthe antiprogestin RU486
Since an antioestrogen can inhibit oestrogen and progestin-
mediated MCF-7 cell proliferation, we next tested whether
the antiprogestin RU486 could influence the cell stimulation.
The proliferative effects of varying concentrations of oest-
radiol and gestodene with and without 10-7 M RU486 on the
growth of MCF-7 cells are shown in Figure 4. The growth
curves are identical with or without the antiprogestin except
at the lowest concentration of agonist. RU486 itself can
stimulate proliferation at 10-7 M, and therefore the initial
increase in growth stimulation is likely to be due to the
antiprogestin. The results with norgestrel with and without
RU486 were similar to the data with gestodene (data not
shown).
Effects ofoestradiol, norgestrel andgestodene on
vit-ERE-CAT activity with and without thepresence ofICI
164,384
The growth assays suggest that the progestins can stimulate
proliferation in a manner similar to oestrogen, and that
antioestrogens (but not antiprogestins) can block this
stimulation. However, the specific intracellular mechanism
involved in this stimulation was still not clear. Therefore, the
CAT assay was used to determine whether the 19-nor proges-
tins tested could act intracellularly in a fashion similar to
oestradiol. Intracellular interaction of oestrogen with its
receptor results in a complex that is capable of binding to a
specific enhancer sequence (known as the oestrogen respon-
pERE15-TK-CAT
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sive element (Figure 5) or ERE) that results in the stimula-
tion of downstream gene transcription. Our experiments
involved the transfection of a plasmid which was constructed
with the perfect palindrome vitERE, the thymidine kinase
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Figure 4 Influence of oestradiol (0) and gestodene (0) on
MCF-7 cells with and without the presence of RU486. The
protocol used in described in the legend under Figure 2. Varying
concentrations of oestradiol plus 10-7 M RU486 are represented
by (0) while varying concentrations of gestodene plus 10-7 M
RU486 are represented by (U). RU486 (0) at 10-7 M has the
ability to stimulate MCF-7 cell proliferation to 15lsg/well, and
therefore the increased growth rate seen at the lowest concentra-
tions of oestradiol and gestodene are due to RU486 stimulation.
Again, norgestrel acted similarly to gestodene in this assay and
was not included for clarity.
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Figure 5 The DNA sequence of the response elements used in this study. The vitERE is a perfect palindrome, while the pS2ERE
has a single base pair change in this palindromic sequence, as well as a base pair change in the 3 bp spacer region. The PRE15
differs substantially from the various ERE sequences.NORGESTREL AND GESTODENE POSSESS OESTROGENIC ACTIVITY
promotor, and finally the chloramphenicol acetyltransferase
gene. Transient transfection with a vitERE-CAT plasmid
construct provided a means of determining if norgestrel and
gestodene were capable of activating the ERE. The results
shown in Figure 5 indicate that oestradiol (at 10-10 M),
norgestrel and gestodene (at 10-6M each) are capable of
stimulating CAT activity above control levels, while MPA is
unable to do so. The addition of the antioestrogen ICI 164,
384 dramatically inhibited the ability of oestradiol, norgestrel
and gestodene to stimulate CAT activity (Figure 6).
Oestradiol, norgestrel andgestodene influence on
pS2ERE-CATactivity
Our next task was to examine whether the interaction was
specific to the ERE palindromic sequence, or whether a
nonspecific interaction within the plasmid was the cause of
our results. In order to determine if the interaction with the
ERE was specific, MCF-7 cells were transfected with
pS2ERE-CAT, the nonperfect palindrome ERE-CAT plas-
mid construct (Figure 5). This ERE has been shown to have
lower affinity for the ER as compared to vitERE. Oestradiol,
norgestrel and gestodene could only weakly stimulate CAT
activity at concentrations that could stimulate strong CAT
activity with the vitERE (Figure 7).
The ability ofnorgestrel, gestodene and oestradiol to regulate
the expression ofprogesterone receptor message
Progesterone receptor expression is known to be increased by
oestradiol in MCF-7 cells (Ree et al., 1989). The level of this
protein can thus be used as a marker for successful oestrogen
receptor activation. We examined the influence of norgestrel
and gestodene on progesterone receptor levels (Figure 7). At
10-8 M, neither gestodene nor norgestrel were able to
stimulate production of progesterone receptor protein. How-
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Figure 6 The influence of oestradiol, norgestrel, gestodene and
MPA on vit ERE-CAT activity with and without the presence of
an antioestrogen. MCF-7 cells were transfected with the vitERE-
CAT plasmid, and then the cells were treated with oestradiol,
norgestrel, gestodene or MPA at the concentrations indicated.
The ability of the cell lysate to convert tritiated chloramphenicol
to acetylated chloramphenicol was measured by chromatography
and scintillation counting. The control lane represents vitERE-
CAT activity in the absence of steroid. The open bars indicate
the various compounds (oestradiol at 10-10 M, gestodene at
10-6 M, norgestrel at 10-6 M and MPA at 10-6M) alone, while
the hatched bars indicate these compounds (at the concentrations
indicated) in the presence of ICI 164,384 at 10-6 M.
21.7
c
o 1.6
L1.5-
o 1.4
1.3-
U-1.2
1.1
1.0
0.9
o 0 (
o 0
Compounds tested
Figure 7 The influence of oestradiol, gestodene, and norgestrel
on pS2ERE-CAT activity. The protocol used is described in
Figure 5, with the exception that the pS2ERE-CAT plasmid was
used rather than the vitERE-CAT. The control level represents
pS2ERE-CAT activity in the absence of steroid. The open bars
represent 10-I° 0M oestradiol, Ilo-6 IM gestodene, I0-6 IM norgestrel,
respectively. The hatched bars represent these compounds (at the
concentrations indicated) in the presence of ICI 164,384 at
10-6 M. The influence of MPA on CAT expression was weaker
than all other compounds tested (data not shown).
ever, at 106 M, both compound could stimulate progesterone
receptor production. MPA could not stimulate progesterone
receptor levels at either of these concentrations.
PRE-CATactivity by oestradiol, norgestrel, gestodene and
MPA with and without the antiprogestin RU486
Our results to this point suggested that the progestins acted
as oestrogens in our model system. It was therefore impor-
tant to show that the progestins could also interact with the
progesterone receptor and induce transcription of genes
located near a PRE (Figure 5). However, progestin inter-
action with the progesterone receptor down-regulates recep-
tor production (VuHai et al., 1978), and at lower concentra-
tions, the progestins did not provide an oestrogen-like
stimulation of the progesterone receptor. As a result oest-
rogen was added to the medium to boost progesterone recep-
tor production. We then transiently transfected a PRE15-
CAT plasmid contruct into MCF-7 cells. Results shown on
Figure 8 indicate that norgestrel and gestodene are capable
of stimulating CAT activity at a lower concentration than the
concentration capable of stimulating cell proliferation. MPA
could stimulate PRE15-CAT activity despite an inability to
stimulate cell proliferation (data not shown). The PRE15-
CAT stimulation by norgestrel and gestodene could be
blocked by the antiprogestin RU486, whereas RU486 could
not block MCF-7 cell proliferation in the growth assays.
Incidentally, without oestradiol boost, norgestrel and ges-
todene could still stimulate PRE-CAT expression in this
system at 10-6 M (a concentration sufficiently oestrogenic to
boost progesterone receptor (Table I)), while MPA could not
(data not shown).
Discussion
Our results demonstrate that the 19-nortestosterone
derivatives norgestrel and gestodene stimulate MCF-7 cell
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Table I Progesterone receptor enzyme immunoassay determination
of progesterone receptor regulation in MCF-7 cells by oestradiol,
norgestrel, gestodene and MPA. The values given are fmolmg'
protein and are done in duplicate
Progesterone receptor content
Compounds (fmolmg-' protein)
Control 4.21 +/-0.74
Oestradiol (10-11 M) 128.10 +/-10.93
Oestradiol (10-lOM) 323.36 +-54.56
Norgestrel (10-8 M) 2.82 +/-0.00
Norgestral (10-6M) 26.24 +/-2.75
Gestodene (10-8 M) 3.22 +/- 0.22
Gestodene (10-6 M) 82.04 +-2.4
MPA (10-8M) 3.56 +/-1.44
MPA (10-6M) 3.73 +/-0.35
proliferation by activating the oestrogen receptor. Norgestrel
and gestodene were capable of stimulating MCF-7 cell pro-
liferation in vitro, although they were both less potent and
less efficaceous when compared to oestradiol. The stimulation
could be blocked by the antioestrogen ICI 164,384 but not
by the antiprogestin RU486. We showed that these proges-
tins could activate CAT transcription specifically at the vitel-
logenin oestrogen responsive element (vit ERE), and this
interaction could be blocked by ICI 164,384. We further
showed that norgestrel and gestodene could increase pro-
gesterone receptor levels, a common marker for oestrogen
receptor-mediated transcription.
The progestins norgestrel and gestodene have previously
been shown to act differentially in cultured human breast
cancer (Iqbal et al., 1986). Despite minor structural
differences between the two compounds, the authors had
found that gestodene could bind to receptors specific to
malignant breast tissue while norgestrel could not. Such bin-
ding resulted in growth inhibition. It is surprising that an
endogenous receptor should have such high substrate
specificity among synthetic progestins. Our results suggest
that gestodene and norgestrel act similarly, as would be
expected from their structures.
The 19-norprogestins norgestrel and gestodene are capable
of stimulating MCF-7 cell growth via interaction with the
oestrogen receptor. Oestrogenic potential of progestins is
further supported by the recent work of Markiewicz et al.
(1992). This stimulation occurs in a concentration dependent
fashion, and can be inhibited by the pure antioestrogen ICI
164, 384. However, the finding that the antiprogestin RU486
is incapable of inhibiting progestin stimulated growth sug-
gests that the growth stimulatory interaction is not mediated
via the progestin receptor. This conclusion is supported by
the inability of MPA to stimulate growth (Figure 1) or to
stimulate vitERE-CAT activity (Figure 5) while the capable
of stimulating PRE15-CAT activity as much as 150% (data
not shown).
Although norgestrel and gestodene are capable of
stimulating PRE15-CAT activity at very low concentrations
(Figure 8), the progestational activity of these compounds do
not appear to provide an attenuating effect of their
oestrogen-like activity. The MCF-7 cell line proliferates in
the presence of the progestin despite the presence of func-
tional PR. We have also tested various 19-norprogestins in
the T-47D cell line and have found similar stimulatory
activity (unpublished observations). Based upon the correla-
tion between the concentration of progestin required for
vitERE-CAT activity and growth stimulation, it is likely that
the growth stimulation is mediated via the oestrogen receptor
rather than via the progesterone receptor.
The ability of norgestrel to provide effective birth control
without the presence of an oestrogen (for example, the
minipill and NORPLANT® formulations) had previously
been inconsistent with our understanding of progestin
biochemistry. If the progestin only acted through the pro-
gesterone receptor, the receptor should be downregulated and
eventually result in the ineffectiveness of norgestrel. We sug-
gest that norgestrel is also capable of interacting with the
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Figure 8 The influence of gestodene and norgestrel on PREIS-
CAT activity with and without the presence of an antiprogestin.
Column 1 represents media with 10-10M oestradiol (see results
section for explanation). All other lanes have 1010M oestradiol
in combination with the steroid given. The open bars represent
the steroid alone, while the hatched bars represent the steroid
combined with 10-7M RU486. The transfection procedure was
similar to that described in the caption for Figure 5, except that
the PRE1S-CAT plasmid construct was used and the pro-
gesterone receptor was boosted by adding oestradiol to the
media.
oestrogen receptor, thus resulting in stimulation of pro-
gesterone receptor synthesis and maintained progestational
activity.
It is noteworthy that the 19-norprogestins are capable of
stimulating MCF-7 cell growth at concentrations as low as
10- M or 30 ng ml-'. Such concentrations are similar to
plasma progestin concentrations seen in women who use oral
contraceptives (Orme et al., 1983; Goldzieher, 1989). Plasma
progestin concentrations seen in NORPLANT® users
(0.5 nl ml-' or approximately 10-10 M) are low enough to
provide no growth stimulus above control in our model
system (Croxatto et al., 1988; Shoupe & Mishell, 1989,
Shoupe et al., 1991). Therefore, NORPLANT®D may offer
advantages over the oral contraceptives by being effective at
concentrations below those that stimulate breast cancer cell
proliferation.
We suggest that the lowest effective concentration of 19-
norprogestins should be pursued. Although developing lower
dose formulations has been a priority for hormonal con-
traceptive manufacturers, our results indicate that the present
progestin concentrations are still capable of stimulating
human breast cancer. Furthermore, the assumption that
progestin-only formulations are devoid ofoestrogenic activity
appears to be incorrect. For the present time, oral contracep-
tives should be measured by their total oestrogenicity (i.e. the
oestrogen activity of oestrogen plus the oestrogenic activity
of the progestin) in order to provide the most prudent and
protective means of contraception. This oestrogenicity may
also be determined for various formulations used in
epidemiological studies that compare oral contraceptive use
and breast cancer incidence, and may be one of the distin-
guishing characteristics betweens the conflicting results of
these studies.
This research was sponsored by National Medical Fellowships, Inc.
and National Institutes of Health grant RO1-32713-10 for cancer
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